Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A phase 3 trial just delivered a major win for patients with platinum-resistant ovarian cancer. Rinatabart sesutecan (Rina-S), an antibody-drug conjugate, cut the risk of disease progression by 71% and the risk of death by 57% compared to standard chemotherapy. Crucially, these benefits held regardless of folate receptor alpha (FRα) expression levels, opening the door to a broader patient population.
A phase 3 trial just delivered a major win for patients with platinum-resistant ovarian cancer. The RAINFOL-02 trial found that rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), significantly outperformed investigator's-choice chemotherapy on both progression-free survival (PFS) and overall survival (OS) — and it worked across the board, regardless of folate receptor alpha (FRα) expression levels.
Rina-S works by targeting FRα on tumor cells, delivering a topoisomerase I inhibitor (exatecan) directly inside the cell to disrupt DNA replication and trigger tumor cell death. The trial enrolled 584 patients with high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer who had received 1–4 prior lines of therapy. No new safety signals emerged.
By the Numbers:
Why it matters: Platinum-resistant ovarian cancer carries a grim prognosis with very few effective options. Rina-S's ability to improve both PFS and OS — independent of FRα expression — could make it a broadly applicable treatment if approved, potentially reshaping the standard of care for this difficult-to-treat population.
